Donald Hayden
Chairman at AVANIR PHARMACEUTICALS INC
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Bradley Campbell | M | 48 | 18 years | |
Will Lewis | M | 55 | 12 years | |
S. Schaeffer | F | 55 | 19 years | |
Sandra Leung | F | 63 | 32 years | |
Eugene Jeffrey Sullivan | M | 59 | 9 years | |
Alexandra Glucksmann | M | 65 | 6 years | |
Al Altomari | M | 65 | 12 years | |
Ellen Rosenberg | F | 61 | 8 years | |
Drayton Wise | M | 49 | 10 years | |
Roger Adsett | M | 55 | 8 years | |
Yao Lee | M | 54 | 6 years | |
Elizabeth Anderson | F | 66 | 6 years | |
Shiva G. Fritsch | F | - | 7 years | |
Kimberly Noonan | M | - |
WindMIL Therapeutics, Inc.
WindMIL Therapeutics, Inc. Medical SpecialtiesHealth Technology WindMIL Therapeutics, Inc. operates as a biotechnology company. It develops immunotherapies for the treatment of cancer patients. The company was founded by Ivan Borrello and Kimberly Noonan and is headquartered in Baltimore, MD. | 8 years |
Karen LaRochelle | F | 57 |
WindMIL Therapeutics, Inc.
WindMIL Therapeutics, Inc. Medical SpecialtiesHealth Technology WindMIL Therapeutics, Inc. operates as a biotechnology company. It develops immunotherapies for the treatment of cancer patients. The company was founded by Ivan Borrello and Kimberly Noonan and is headquartered in Baltimore, MD. | 25 years |
Michael Smith | M | 47 | 10 years | |
Kimberly McCutcheon Jablonski | F | - | 21 years | |
Kelly Parker | M | - | 9 years | |
Ram Palanki | M | 48 | 6 years | |
Kabir Kumar Nath | M | 59 |
Otsuka America Pharmaceutical, Inc.
Otsuka America Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Otsuka America Pharmaceutical, Inc. manufactures and supplies pharmaceutical products. It develops drugs for neuroscience, cardiovascular, and gastrointestinal treatments. The company was founded in 1989 and is headquartered in Rockville, MD. | 8 years |
Daniel Tassé | M | 64 | 8 years | |
David Stump | M | 74 | 9 years | |
Margaret McGlynn | F | 64 | 15 years | |
Craig Wheeler | M | 63 | 8 years | |
Argeris Karabelas | M | 71 | 9 years | |
David McGirr | M | 69 | 11 years | |
Glenn Sblendorio | M | 68 | 18 years | |
Robert McQuade | M | 67 |
Otsuka America Pharmaceutical, Inc.
Otsuka America Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Otsuka America Pharmaceutical, Inc. manufactures and supplies pharmaceutical products. It develops drugs for neuroscience, cardiovascular, and gastrointestinal treatments. The company was founded in 1989 and is headquartered in Rockville, MD. | - |
David Brennan | M | 70 | 10 years | |
Curran Simpson | M | 62 | 9 years | |
Lynn Bleil | F | 60 | 6 years | |
Mark McDade | M | 69 |
WindMIL Therapeutics, Inc.
WindMIL Therapeutics, Inc. Medical SpecialtiesHealth Technology WindMIL Therapeutics, Inc. operates as a biotechnology company. It develops immunotherapies for the treatment of cancer patients. The company was founded by Ivan Borrello and Kimberly Noonan and is headquartered in Baltimore, MD. | - |
Patrick Christmas | M | 53 | 8 years | |
Dan Dalton | M | - | 8 years | |
Anna Phil | M | 36 |
WindMIL Therapeutics, Inc.
WindMIL Therapeutics, Inc. Medical SpecialtiesHealth Technology WindMIL Therapeutics, Inc. operates as a biotechnology company. It develops immunotherapies for the treatment of cancer patients. The company was founded by Ivan Borrello and Kimberly Noonan and is headquartered in Baltimore, MD. | 6 years |
David Clark | M | 49 | 6 years | |
Patrick Dougherty | M | - |
WindMIL Therapeutics, Inc.
WindMIL Therapeutics, Inc. Medical SpecialtiesHealth Technology WindMIL Therapeutics, Inc. operates as a biotechnology company. It develops immunotherapies for the treatment of cancer patients. The company was founded by Ivan Borrello and Kimberly Noonan and is headquartered in Baltimore, MD. | 6 years |
Aneta Ferguson | F | - | 9 years | |
Daniel O’Donnell | M | - |
WindMIL Therapeutics, Inc.
WindMIL Therapeutics, Inc. Medical SpecialtiesHealth Technology WindMIL Therapeutics, Inc. operates as a biotechnology company. It develops immunotherapies for the treatment of cancer patients. The company was founded by Ivan Borrello and Kimberly Noonan and is headquartered in Baltimore, MD. | - |
Jerome W. Jackson | M | - | 9 years | |
Samantha Prout | F | 46 | 6 years | |
Howard Soule | M | - |
WindMIL Therapeutics, Inc.
WindMIL Therapeutics, Inc. Medical SpecialtiesHealth Technology WindMIL Therapeutics, Inc. operates as a biotechnology company. It develops immunotherapies for the treatment of cancer patients. The company was founded by Ivan Borrello and Kimberly Noonan and is headquartered in Baltimore, MD. | - |
Ambrose Bailey | M | 60 | 8 years | |
Stephen M. Kaufhold | M | - | 8 years | |
Patrik Florencio | M | - | 9 years | |
Hisanori Maei | M | - | 9 years | |
Olivier Danos | M | 66 | 7 years | |
Thomas DesRosier | M | 69 | - | |
Walter R. Perkins | M | - | 14 years | |
Diana Moore | F | - | 9 years | |
Robert Sedor | M | - | 9 years | |
Stephen Pakola | M | 55 | 5 years | |
Monil Shah | M | - |
WindMIL Therapeutics, Inc.
WindMIL Therapeutics, Inc. Medical SpecialtiesHealth Technology WindMIL Therapeutics, Inc. operates as a biotechnology company. It develops immunotherapies for the treatment of cancer patients. The company was founded by Ivan Borrello and Kimberly Noonan and is headquartered in Baltimore, MD. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Giovanni Caforio | M | 59 | 24 years | |
Lamberto Andreotti | M | 73 | 19 years | |
Jeffrey Hatfield | M | 66 | 31 years | |
Peter R. Dolan | M | 68 | 18 years | |
Benjamin Auspitz | M | 51 | - | |
Iain Dukes | M | 65 | 7 years | |
Mary Thistle | F | 64 | 2 years | |
Thomas R. Beck | M | 74 | - | |
Nicholas Lee Gurreri | M | - |
Transave, Inc.
Transave, Inc. Pharmaceuticals: MajorHealth Technology Transave, Inc. is a biopharmaceutical company focused on developing innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. They are committed to significantly improving the quality of life and healthcare of patients suffering from these life-threatening diseases. Its operating principles are centered on teamwork, openness, mutual respect, diversity of opinion, trust, accountability and innovative science. They are developing products based on Transave's proprietary liposomal technology designed specifically for lung delivery. Its focus is on reformulating off-patent, established drugs into unique liposomal technology - based inhaled pharmaceuticals for the localized, site-specific treatment of serious lung diseases. Transave's proprietary liposomal technology allows for the sustained release of a drug in the lung's microenvironment. By remaining in the lungs for a prolonged period and potentially minimizing systemic exposure, Transave's liposomal technology offers the potential for changing the product profile, improving delivery of the compound to the lung and enhancing the therapeutic index of established pharmaceuticals. | - |
James Cornelius | M | 81 | 10 years | |
Charles A. Heimbold | M | - | 20 years | |
Michael Dybbs | M | 49 | 2 years | |
Rishi Gupta | M | 46 | - | |
Blaine Davis | M | 50 | 3 years | |
William Shakespeare | M | 60 | 6 years | |
John E. Celentano | M | 64 | 31 years | |
Timothy Clackson | M | 58 | 2 years | |
Myrtle Potter | F | 65 | 9 years | |
Timothy G. Whitten | M | 67 |
Transave, Inc.
Transave, Inc. Pharmaceuticals: MajorHealth Technology Transave, Inc. is a biopharmaceutical company focused on developing innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. They are committed to significantly improving the quality of life and healthcare of patients suffering from these life-threatening diseases. Its operating principles are centered on teamwork, openness, mutual respect, diversity of opinion, trust, accountability and innovative science. They are developing products based on Transave's proprietary liposomal technology designed specifically for lung delivery. Its focus is on reformulating off-patent, established drugs into unique liposomal technology - based inhaled pharmaceuticals for the localized, site-specific treatment of serious lung diseases. Transave's proprietary liposomal technology allows for the sustained release of a drug in the lung's microenvironment. By remaining in the lungs for a prolonged period and potentially minimizing systemic exposure, Transave's liposomal technology offers the potential for changing the product profile, improving delivery of the compound to the lung and enhancing the therapeutic index of established pharmaceuticals. | 2 years |
John M. McAdam | M | 49 | 4 years | |
Dee Grosso | F | - |
Transave, Inc.
Transave, Inc. Pharmaceuticals: MajorHealth Technology Transave, Inc. is a biopharmaceutical company focused on developing innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. They are committed to significantly improving the quality of life and healthcare of patients suffering from these life-threatening diseases. Its operating principles are centered on teamwork, openness, mutual respect, diversity of opinion, trust, accountability and innovative science. They are developing products based on Transave's proprietary liposomal technology designed specifically for lung delivery. Its focus is on reformulating off-patent, established drugs into unique liposomal technology - based inhaled pharmaceuticals for the localized, site-specific treatment of serious lung diseases. Transave's proprietary liposomal technology allows for the sustained release of a drug in the lung's microenvironment. By remaining in the lungs for a prolonged period and potentially minimizing systemic exposure, Transave's liposomal technology offers the potential for changing the product profile, improving delivery of the compound to the lung and enhancing the therapeutic index of established pharmaceuticals. | - |
Annalisa Jenkins | M | 58 | 3 years | |
Jean Franchi | F | 57 | 2 years | |
Geoffrey P. Gilmore | M | 58 | 15 years | |
Charles Rowland | M | 65 | 11 years | |
Charles Bancroft | M | 65 | 36 years | |
Randall W. Whitcomb | M | 69 | 14 years | |
Tricia Truehart | F | - | 3 years | |
Jason Haddock | M | 54 | 14 years | |
Peter M. Clarke | M | 64 | - | |
Kathy Yi | F | 52 | 3 years | |
Christine Pellizzari | F | 56 | 8 years | |
Daniel Abdun-Nabi | M | 69 | 6 years | |
Brian Daniels | M | 65 | 14 years | |
Matt Patterson | M | 52 | 6 years | |
Luke Beshar | M | 65 | 6 years | |
James Topper | M | 62 | 11 years | |
Carl Gordon | M | 59 | 6 years | |
Kevin P. Tully | M | 70 | 6 years | |
Ted Love | M | 65 | 8 years | |
Leif Valdemar Johansson | M | 73 | 13 years | |
Lewis B. Campbell | M | 77 | 18 years | |
Béatrice J. Cazala | F | 67 | 32 years | |
Lawrence Hamilton | M | 66 | 8 years | |
Louis J. Freeh | M | 74 | 8 years | |
Georges Gemayel | M | 64 | 2 years | |
Michael Rome | M | 39 | 3 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Donald Hayden
- Personal Network